Introduction {#S1}
============

Gamma-butyric acid (GABA) is the primary inhibitory neurotransmitter in the mammalian brain^[@R1]^. GABA dysfunction has been implicated in the pathophysiology and cognitive deficits of schizophrenia, mainly based on post-mortem and preclinical research^[@R2],\ [@R3]^. Reduced expression of GAD67, a GABA synthesis enzyme, is a well-replicated molecular finding in schizophrenia^[@R4]--[@R7]^. GABAergic interneurons are thought to facilitate the rhythmic entrainment of pyramidal cell discharge and their abnormalities may lead to cognitive dysfunctions, especially working memory impairments, in schizophrenia^[@R2],\ [@R8]--[@R11]^. Because GABA plays a critical role in brain functions in general and in schizophrenia in particular, emerging techniques to achieve more accurate measurements of GABA concentrations in patients with schizophrenia *in vivo* will play a critical role in advancing pathophysiological and pharmacological research in schizophrenia.

Proton magnetic resonance spectroscopy (^1^H-MRS) techniques such as spectral editing, also widely known as "MEGA-PRESS," (MEGA-Point REsolved Spectroscopy Sequence) have enabled quantification of brain GABA concentrations *in vivo*^[@R12]^. With the traditional MEGA-PRESS, the frequency selective pulses are placed at 1.9 and 7.5ppm, and macromolecules coedit with the GABA signal. As a result, macromolecules contribute up to 50% of the GABA signal^[@R13]^. This measurement is typically denoted as "GABA+".

Several MRS studies of schizophrenia have reported abnormal but inconsistent findings, including increased^[@R14],\ [@R15]^ or reduced GABA+ levels^[@R16]--[@R19]^ in schizophrenia, depending upon antipsychotic and concomitant medication status, illness duration, and brain region. There is currently no consensus in the field as to whether the differences between schizophrenia and normal control participants are present or due to differences in macromolecules, GABA, or a combination. The inconsistency is reminiscent of earlier MRS findings in glutamate, although subsequent evidence suggests that glutamate was elevated in younger schizophrenia patients^[@R20]--[@R22]^, but reduced in chronic, older patients^[@R18],\ [@R23]^. Interestingly, our preliminary analysis of GABA+ aging trend, using the traditional MEGA-PRESS method, showed a similar trend of age-related reduction of GABA levels in patients with schizophrenia^[@R18]^. Motivated by these prior observations, our study included an adequately powered sample to examine the schizophrenia diagnosis by age cohort effect on GABA concentration, and utilized a critically improved GABA assessment technique that removes the macromolecule contamination.

To address this, we employed MEGA-PRESS with frequency selective pulses at 1.9 and 1.5ppm^[@R24]^ to assess macromolecule-suppressed GABA in a cohort of participants with schizophrenia and psychiatrically healthy controls. We tested the hypothesis that older participants with schizophrenia would have lower anterior cingulate GABA levels compared to older control participants. We predicted that there would be no significant difference between younger participants with schizophrenia and controls.

This study also examined the relationships between GABA and psychiatric symptoms severity in positive and negative symptoms, and cognitive functions in working memory, processing speed, functional capacity. Based on the strong evidence supporting GABAergic function in working memory^[@R2],\ [@R25]^, we predicted that GABA level would play a stronger role in working memory compared with other clinical, cognitive, and functional measures.

Methods {#S2}
=======

Participants {#S3}
------------

One-hundred and forty-five participants completed this study but 8 were excluded due to poor data quality, leaving a total of 29 younger and 31 older in the schizophrenia group and 40 younger and 37 older in the control group. Participants with schizophrenia had diagnosis of schizophrenia (n=50) or schizoaffective disorder (n=10) as determined with the Structured Clinical Interview for DSM-IV-TR, Patient Version. Normal controls had no past or present Axis I psychiatric disorder as determined with the Structured Clinical Interview for DSM-IV-TR, Non-Patient Version. All participants were 18--65 years old, with no current or past neurological condition and major medical conditions, and no DSM-IV-TR substance abuse in the last 6 months or substance dependence in lifetime or 1 year or more (except nicotine). We made attempt to frequency-match the smoking status between patients and controls (see [Table 1](#T1){ref-type="table"}). Participants with schizophrenia were evaluated for their ability to provide informed consent before signing consent documents. All participants gave written informed consent prior to participation in the study. This study was approved by the University of Maryland Baltimore Institutional Review Board.

Patients were evaluated for psychopathology with the Brief Psychiatric Rating Scale (BPRS) and the Brief Negative Symptom Scale (BNSS)^[@R26]^. Five patients were not on antipsychotics (2 in the younger vs. 3 in the older group), 5 only on typical (1 vs. 4), and 50 on atypical antipsychotics (26 vs. 24) (χ^2^ = 2.02, p=0.36). Seven of those on atypicals were also on typical antipsychotics (1 vs. 6). Of the atypical antipsychotics, 15 were on clozapine (7 vs. 8), 14 on risperidone (8 vs. 6), 7 on olanzapine (3 vs. 4), 2 on paliperidone (1 vs. 1), 6 on quetiapine (3 vs. 3), 5 on aripiprazole (4 vs. 1), and 1 on ziprasidone (0 vs. 1). Patients on daily use of benzodiazepines or nonbenzodiazepine GABAergic hypnotics were excluded. Three patients (1 vs. 2) were on the anticholinergic drug benztropine; patients with clinically uncontrolled extrapyramidal symptoms or tardive dyskinesia were excluded. Participants completed a targeted cognitive/functional capacity battery of three measures: processing speed by the digit symbol coding test^[@R27]^, working memory by the digit sequencing test^[@R28]^, and functional capacity was assessed with the UPSA-2^[@R29]^. While cognitive deficits in schizophrenia encompass multiple domains, deficits in working memory^[@R30]--[@R32]^ and processing speed^[@R33]--[@R35]^ are particularly severe. The UCSD Performance-based Skills Assessment (UPSA-2) was used to measure functional capacity. UPSA-2 uses role-play to assess functioning across five domains: organization/planning, financial skills, communication skills, transportation, and household skills, and is a validated tool to assess community functional capacity in schizophrenia patients^[@R36]^. Nine controls and 3 participants with schizophrenia did not complete UPSA or processing speed testing and 12 controls and 4 participants with schizophrenia did not complete digit span testing. Participants were monetarily compensated for their time.

MRS Acquisition and Analyses {#S4}
----------------------------

MR scanning was conducted on a 3T Siemens Tim Trio equipped with a 32-channel head coil. Head position was fixed with foam padding to minimize movement. Anatomical T1-weighted images were acquired for spectroscopic voxel placement with a 'MP-RAGE' sequence^[@R37]^. For detection of GABA, spectra were acquired from a medial frontal region that included the anterior cingulate (Brodmann areas 24 and 32) using a macromolecule-suppressed MEGA-PRESS sequence: TR=2000, TE=68 ms, 20.36 ms length and 44 Hz bandwidth full width at half maximum (FWHM) editing pulses applied at 1.9 (ON) and 1.5 (OFF) ppm, and 256 averages (128 ON and 128 OFF); water unsuppressed 16 averages. Water suppression was achieved using Siemens modified WET water suppression technique. Automated shimming followed by manual shimming was conducted to achieve approximately 12Hz water linewidth. Spectral acquisition methodology was similar to Aufhaus et al^[@R13]^ including the sequence, voxel and saturation bands placement. The 40 × 30 × 20 mm voxel was prescribed on the midsagittal slice and positioned parallel to the genu of the corpus callosum and scalp with the midline of the voxel corresponding to the middle of the genu of the corpus callosum. [Figure 1](#F1){ref-type="fig"} illustrates comparison of conventional and macromolecule-suppressed spectra.

Quantification was conducted with GANNET 2.0 toolkit, a Matlab program specifically developed for analysis of GABA MEGA-PRESS spectra^[@R38]^. Individual spectra were frequency and phase corrected, and then "ON" and "OFF" subtracted resulting in the edited spectrum. The edited GABA peak was modeled as a single-Gaussian and values of GABA relative to water (modeled as a mixed Gaussian-Lorentzian) in institutional units were produced. The normalized fitting residual was calculated by dividing the standard deviation of the fitting residual by the amplitude of the fitted peak. Spectra were included if the normalized fitting residual of GABA was below 15%. The spectroscopic voxel was segmented into gray, white, and CSF tissues using SPM8 and in house MATLAB code, and GABA concentrations were corrected for the proportion of gray, white, and CSF tissue proportions^[@R39]^ (See [Supplementary Materials](#SD1){ref-type="supplementary-material"}). See [Figure 1](#F1){ref-type="fig"} for illustration of voxel location, representative spectrum, and GABA peak fit.

Statistical Analysis {#S5}
--------------------

Demographic variables were analyzed with chi-square or Fisher's exact tests for categorical data and ANOVAs for continuous variables. Participant assignment to age group was determined by median split of age (35 years old). GABA levels were analyzed with a 2(diagnosis) × 2 (age group) ANOVA. Gender and smoking status were included as covariates since previous literature reported GABA+ age related decline differed between males and females^[@R40]^ and GABA+ may be impacted by smoking and sex^[@R41]^. Also, smoking status was different between diagnostic groups (see below). Significant effects (p \< 0.05) were followed-up with post-hoc tests when appropriate. Given the strong interest in GABA and age, the relationship between age and GABA levels per diagnostic group was investigated with linear regressions, as well as by LOESS^[@R42]^, a nonparametric smoothing method where the predicted value for each data point is estimated from a polynomial fitted on nearby data points. LOESS is useful for exploratory analysis of relationships between two variables, such as developmental changes with age, in which a simple global regression function (such as a straight line) cannot be assumed to apply throughout the range of the independent variable. Applications of both linear and LOESS models for the relationship of GABA and age by diagnostic group were conducted. The differences in regression slopes (based on linear regression) between groups were examined by analysis of covariance (ANCOVA) where we tested the effect of group on GABA level while controlling for age. The regression lines were compared by testing the interaction. A significant interaction indicates that the effect of age on GABA level depends on group^[@R43]^. Finally, we also compared the correlation coefficients between groups using Fisher\'s z-transform^[@R44]^.

The relationships between GABA levels and BPRS total and positive symptoms and BNSS negative symptoms in patients with schizophrenia were analyzed using Pearson product moment correlation with Bonferroni correction for three comparisons (p ≤ 0.017). Linear regression analyses were used to test whether GABA levels predict working memory, processing speed, and/or functional capacity after covarying out effects of diagnosis and age that are known to impact cognition and functional capacity. The three regression models tested were: working memory (then replaced by processing speed, and then functional capacity) = b0 + b1\*diagnosis + b2\* age + b3\*GABA level, with significance level set at p ≤ 0.017 after Bonferroni correction for three comparisons. Based on extensive evidence of GABAergic signaling on working memory, we predicted that GABA could have a more robust contribution to working memory. Analyses were conducted with the Statistical Package for Social Sciences (SPSS) version 22.0 software package.

Results {#S6}
=======

Participant characteristics {#S7}
---------------------------

Participant demographic, clinical, and cognitive characteristics by diagnostic and age group are provided in [Table 1](#T1){ref-type="table"}. As expected, the duration of illness was significantly shorter for the younger (5.6 years) compared to the older (24 years) participants with schizophrenia (p \< 0.001). There were no significant differences in psychiatric symptom severity (all p's \> 0.4) or antipsychotic medication status (Fisher's exact test, p \> 0.1) between the younger and older schizophrenia groups. Participants with schizophrenia had significantly fewer years of education (average of 1.7yrs) compared to the control group as illustrated by a main effect of diagnostic group (F(1, 134)=18.7, p \< 0.001).

There were main effects of diagnostic group such that the schizophrenia group had lower working memory (F(1,109)=11.1, p =0.001), processing speed (F(1,120=10.3, p =0.002), and functional capacity UPSA scores (F(1,121) = 39.6, p \< 0.001) compared to the control group. Age group main effects also emerged such that the older groups performed worse in processing speed (F1,121)= 10.4, p = 0.002) and functional capacity (F(1,121)=9.1, p = 0.003). There were no significant diagnostic group by age group interactions for either of the cognitive measures. There were no significant differences in age, gender, smoking status among diagnostic by age groups. There was a trend for more smokers in the schizophrenia group collapsed across age group (Chi square = 3.7, p = 0.055).

GABA levels {#S8}
-----------

Eight spectra from five control and three schizophrenia participants were discarded due to excessive movement resulting in normalized fitting residual \> 15%. All included spectra had a normalized fitting residual of 12% or lower, which did not differ between diagnostic by age groups (p=0.2) but did significantly differ between diagnostic group (p = 0.03; control mean: 6.7% (1.8), schizophrenia mean: 7.4% (2.0). However, inclusion of the normalized fitting residual as a covariate did not change the statistical results. There were no significant differences in the proportion of voxel gray, white, and CSF tissues between diagnostic group by age group, but both older groups had less gray matter (p=0.004). The inclusion of gray matter as a covariate did not alter the results.

Results of age group × diagnostic group ANOVA with gender and smoking as covariates revealed a significant diagnosis by age interaction (F(1,132) = 5.9, p = 0.017) indicating that GABA levels declined from younger to older groups in schizophrenia but less so in the control sample. Results of analysis of simple effects supported our a priori hypothesis that GABA levels were significantly lower in the older participants with schizophrenia compared to older controls (t (66)= 3.1, p =0.003) but not between the younger control and schizophrenia groups (t (67)=0.25, p=0.994). See [Figure 2](#F2){ref-type="fig"} that illustrates GABA levels by age and diagnostic group.

The relationship between GABA and age {#S9}
-------------------------------------

Linear regression analyses revealed that age strongly predicted GABA levels in the schizophrenia group (B = −0.6, t(59) = −6.42, p \< 0.001, R^2^=0.42) accounting for 42% of variance, but the effect of age was less in the control group (B = −0.24, t(75) = −2.1, p = 0.036, R^2^= 0.057) accounting for 5.7% of the variance (See [Figure 3](#F3){ref-type="fig"}). The slope of the age effect was significantly different (t = −2.86, df = 132, p = 0.005) and the correlation coefficients of the age vs. GABA effect were also significantly different between groups (z = 2.97, p = 0.0015). This suggests there was a significantly steeper age-related decline in GABA level in schizophrenia compared with the age-related decline in controls, and that age explained significantly more of the individual variance in GABA level in schizophrenia compared with controls. Application of LOESS model to data suggested similar, gradually increasing GABA levels among schizophrenia and controls groups until around 33 years old after which GABA declined in both groups, with a steeper, continuous decline (See [Figure 3](#F3){ref-type="fig"}) in the schizophrenia group, and a tendency for average decline to level off after age 50 in the control group.

Illness duration was significantly related to GABA levels (r=−0.63, p\<0.001) in the patients. This was to be expected since age is strongly related to illness duration. However, using age as the control variable, the partial correlation of GABA level and illness duration was no longer significant (r=−0.13, p=0.35). In comparison, when illness duration is used as the control variable, age remains significantly correlated with GABA level (r=−0.37, p=0.007). Age plays a significant role even when illness duration is taken into account.

GABA and symptoms and cognition {#S10}
-------------------------------

There were no statistically significant relationships between GABA and BPRS positive and total scores or negative symptom score measured by BNSS (all p's \> 0.8).

Linear regression analysis revealed that GABA level significantly predicted working memory (F=7.5, p \<0.001, R^2^=0.17) in the overall model. GABA level was positively and significantly associated with working memory (t=2.96, p=0.004) when diagnosis and age were controlled. Diagnosis (t=2.7, p=0.008) but importantly not age (t=0.31, p=0.76) predicted working memory. Repeating the above analysis for functional capacity, the model was again significant (F=15.6, p \<0.001, R^2^=0.28,), although only diagnosis (t=5.7, p\<0.001) but not age (t=1.7, p = 0.10) or GABA (t=1.2, p=0.23) was a significant contributor to functional capacity. Finally, the model for processing speed was also significant (F=5.0, p =0.003, R^2^=0.13), although only age (t=2.0, p = 0.047) and diagnosis (t=3.0, p=0.003), but not GABA (t=0.19, p=0.85) were significant contributors to processing speed. Therefore, medial frontal/anterior cingulate GABA level was a significant predictor for working memory; while for processing speed or functional capacity, only diagnosis and/or age but not GABA level were significant predictors.

GABA and antipsychotic medication {#S11}
---------------------------------

Chlorpromazine (CPZ) equivalent units^[@R45]^ did not significantly differ between the younger and older groups (p= 0.50) and were not significantly related to GABA levels (p = 0.90). Moreover, the inclusion of CPZ as a covariate in the omnibus test did not change the interaction results (p = 0.012 vs 0.017).

Participants with schizophrenia were assigned to one of four antipsychotic treatment groups: typical only (n=5), atypical only (n=44), both typical and atypical (n=7), and no medication (n=5). Visual inspection of individual GABA values indicates that GABA levels did not differ between the four antipsychotic drug groups ([Figure 4](#F4){ref-type="fig"}). It is also important to note that the groups did not significantly differ in psychiatric symptom severity or cognitive measures (all p\>0.05). Patients on one vs. two antipsychotics were also not significantly different in positive symptom severity (p=0.81). Removing those patients on two antipsychotics, results of the significant age × diagnostic group interaction remained significant (p values changed from 0.017 to 0.015). Visual inspection of the GABA levels of participants taking 2 antipsychotics were no different from those taking 1 antipsychotic, as illustrated in [Figure 4](#F4){ref-type="fig"}. Six patients were also on a mood stabilizer (5 on valproic acid and 1 on lamotrigine), which could raise GABA levels^[@R15]^. However, all patients were in the older age group and removing them did not change the significant group differences or the age-related correlation in GABA levels. Finally, different antipsychotic medication may affect the GABAergic system differently due to different neurotransmitter binding profiles. Comparing patients on clozapine (n=15) vs. risperidone (n=14), the two medications with the largest participant number and different binding profiles, we found no evidence of a significant difference in GABA levels (0.83±0.18 vs. 0.81±0.16, respectively, F(1,28)=0.11, p=0.78).

Discussion {#S12}
==========

To our knowledge, this is the first study to investigate *in vivo* medial frontal/anterior cingulate GABA levels in schizophrenia using MEGA-PRESS with macromolecule suppression. This is also the largest study of GABA levels in schizophrenia measured with MRS to date. We confirm our previously reported trend finding of reduced medial frontal GABA+ in older schizophrenia using traditional MEGA-PRESS^[@R18]^. It is important to note that this previous work was conducted on a different 3T MR scanner and platform (Philips). The participants in the current study also had no overlap with the previous sample.

Our findings add to the growing literature of GABA+ level alterations measures with MRS in schizophrenia^[@R14],\ [@R15],\ [@R18]^. The result of lower GABA in older participants with schizophrenia may have reconciled the seemingly contradictory observations in several previous reports in schizophrenia. Anterior cingulate GABA+ levels assessed with MRS have been shown to be higher in participants with schizophrenia who were younger and not taking antipsychotic medication (including 9 who were off medication for at least two weeks and 7 were medication-naive)^[@R14]^, and during exacerbation of psychosis^[@R15]^ compared to control participants. The participants assessed here and in our previous work^[@R18]^ were mostly medicated patients across a large age span. The five participants with schizophrenia off medication (for one month or more) did not have higher GABA levels and had a similar relationship between age and GABA to the medicated schizophrenia groups. When considering this and previous studies, it is likely that GABA is higher in younger off-medicated and actively psychotic patients but decreases in older, antipsychotic- medicated patients.

It remains to be determined if GABA levels are greater in a larger cohort of older participants with schizophrenia who are off antipsychotic medication, as perhaps suggested by a GABA+ study^[@R14]^. It is likely that higher GABA levels are restricted to just a small subset of off medication people with schizophrenia since plots of individual subject values in Kegeles et al^[@R14]^ reveal 4 extreme values possibly driving the group effect of higher GABA+ in the off medicated group, reflective of the heterogeneity of the schizophrenia illness. It also remains to be determined if GABA levels are higher in older persons experiencing an exacerbation in psychotic symptoms as suggested by a GABA+/Cr study^[@R15]^. There are substantial methodological differences between the current study and the other studies^[@R14],\ [@R15]^, including the suppression of macromolecules, fitting algorithms used to quantify GABA, thorough correction of GABA levels based on gray, white, and CSF spectroscopic tissue proportions, and GABA relaxation times implemented in this study that deserve mentioning (see Methods).

GABA levels were not related to positive or negative symptoms but were related to cognition, more specifically in working memory, as hypothesized. GABA levels significantly predicted working memory but not functional capacity or processing speed when controlling for age and diagnosis effects. As anticipated, diagnosis strongly contributed to working memory, processing speed, and functional capacity, all of which were significantly impaired in schizophrenia. Functional capacity encompasses multiple cognitive domains and therefore relies on multiple neural networks and mechanisms. Processing speed likely depends on rapid communication among multiple sensory - motor cortical regions, a hypothesis strongly supported by its correlation with widespread white matter integrity^[@R46],\ [@R47]^. In contrast, strong *a priori* evidence suggests that working memory deficits in schizophrenia are related to frontal GABAergic interneuron dysfunction^[@R2],\ [@R25]^. The results of this study are thus consistent with animal models that show working memory deficits induced by disruption of frontal cortex GABA receptors^[@R48]^, as well as preliminary results from an MRS studies suggesting an important role for GABA+ in working memory^[@R49]^. Therefore, treatments targeted at increasing GABA levels may prove beneficial for working memory impairments in schizophrenia^[@R50]^.

There are several outstanding questions regarding interpretation meaning of *in vivo* GABA tissue levels assessed with 1H-MRS. The MRS GABA signal presumably reflects total tissue levels in the voxel of interest. Additional basic science research is needed to determine if the 1H-MRS signal is derived from GABA in all cell types, synapses, extra-synaptic extracellular space, and/or synaptic vesicles. Hence, altered GABA levels in clinical samples cannot be conclusively attributed to alterations in synthesis or specific neuronal mechanisms. Despite these caveats, the finding of the seemingly precipitous decline of GABA levels in schizophrenia over the course of their adult life versus controls could be compatible with post-mortem studies of reduced GAD67, the major enzyme involved in GABA synthesis^[@R7]^ and altered GABAergic interneuron morphology^[@R3]^.

It remains to be determined if lower GABA levels are due to longer antipsychotic medication exposure, illness phase or aging. While we observed an age related decline in GABA within the 5 unmedicated participants, a larger unmedicated sample would be needed to confirm that lower GABA levels are still present without prolonged antipsychotic medication exposure. In psychiatrically normal subjects, one study showed anterior cingulate GABA+/Cr to decline with age^[@R40]^ but another failed to show anterior GABA (with macromolecule suppression) to decline with age^[@R13]^. Our data on the normal controls were consistent with the small decline of GABA over time. The much greater age-related decline in GABA in schizophrenia is thus striking. We propose that this finding is consistent with other neuroimaging studies showing accelerated age-related decline in the brains of schizophrenia patients compared to controls^[@R51],\ [@R52]^. We believe that these data support the hypothesis of accelerated aging in schizophrenia^[@R53],\ [@R54]^.

There are several additional limitations to this study that deserve mentioning. The spectroscopic voxel was large and only one region was assessed. Consequently anatomical specificity was not considered in these results. One previous study suggests that GABA+ differences occur in medial frontal (including ACC) but not dorsolateral prefrontal region^[@R14]^, while another study suggests GABA+ differences in both anterior and posterior cingulate regions^[@R15]^. Therefore, ACC provides a key region for the current study. Future studies should survey multiple brain regions to discern anatomic specificity. Substance use was determined by clinical interview (SCID) and information from the treating clinicians when available, and as such cannot be definitely ruled out as impacting GABA levels. Adherence to antipsychotic medication was based on careful clinical evaluation although not determined through blood testing, which is another limitation. There is the potential confound of antipsychotic medication, which is inherent to the majority of schizophrenia studies, but accounting for CPZ units did not impact results. The heterogeneity of antipsychotic medication is another study consideration since some antipsychotic medications may affect the GABAergic system, and future studies should examine the differential effects of specific antipsychotic medications on GABA levels. The medication subgroups were small and so results should be interpreted with caution.

In conclusion, these data suggest that medial frontal/anterior cingulate GABA levels appear to become lower with advancing age in the schizophrenia group compared to the control group. Developing interventions targeted at increasing GABA levels may improve functional outcomes especially working memory in adult patients with schizophrenia.
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\(a\) Conventional (GABA+) and macromolecule suppressed (GABA) spectra obtained from same individual, (b) Anterior cingulate voxel location with saturation bands (c) representative GABA spectrum, and (d) GABA peak fit in red
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![Mean (SD bars) GABA levels by diagnostic and age groups. There was a significant diagnosis by age interaction (p = 0.017) with lower GABA levels in older schizophrenia compared to older control group (p \< 0.005).](nihms667424f2){#F2}
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The relationship between GABA and age by diagnostic group. Both (a) Linear regression and (b) Loess regression show greater decline in schizophrenia compared to control group.
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![Individual GABA values by antipsychotic drug group.](nihms667424f4){#F4}
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Participant Characteristics. Mean (SD)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                            Schizophrenia\   Control\         Schizophrenia\   Control\
                                                                                                            Younger (n=29)   Younger (n=40)   Older (n=31)     Older (n=37)
  --------------------------------------------------------------------------------------------------------- ---------------- ---------------- ---------------- ---------------
  Gender\                                                                                                   \                \                \                \
    Male/Female                                                                                             20/9             20/20            19/12            25/12

  Age (years)                                                                                               25.7 (4.3)       25.3 (4.6)       48.3 (5.8)       51.0 (6.0)

  [1](#TFN1){ref-type="table-fn"}Education (years)                                                          13.3 (2.1)       14.4 (2.2)       12.7(2.0)        14.9 (2.4)

  [2](#TFN2){ref-type="table-fn"}Smoking status (yes/no)                                                    12/17            10/30            12/19            9/28

  [1](#TFN1){ref-type="table-fn"}.[3](#TFN3){ref-type="table-fn"}Processing speed (digit sequencing test)   63.7 (20.6)      72.0 (19.3)      50.4(15.3)       64.4 (19.5)

  [1](#TFN1){ref-type="table-fn"},[3](#TFN3){ref-type="table-fn"} Functional Capacity (UPSA)                94\. 7 (11.5)    104.2 (7.4)      85.43 (14.8)     101.06 (10.4)

  [1](#TFN1){ref-type="table-fn"}Working memory (digit symbol coding test)                                  42.9 (12.1)      46.1 (13.0)      35.6 (13.6)      47.3 (11.2)

  Duration of illness (years)                                                                               5.6 (4.6)                         24.0 (9.8)       

  Psychiatric Ratings\                                                                                      \                                 \                
    BNSS                                                                                                    15.6 (12.1)                       17.6 (15.4)      

    BPRS (total)                                                                                            39.2 (10.5)                       38.3 (11.5)      

    BPRS (+ subscale)                                                                                       8.4 (4.4)                         8.6 (4.6)        

    BPRS (− subscale)                                                                                       6.6 (2.7)                         6.2 (2.4)        

  Chlorpromazine units (CPZ)                                                                                562.0 (511.4)                     668.9 (643.9)    

  Antipsychotic Medication\                                                                                 \                                 \                
    Typical\                                                                                                1\                                4\               
    Atypical\                                                                                               25\                               18\              
    Both typical and atypical\                                                                              1\                                6\               
    None                                                                                                    2                                 3                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Main effect of diagnostic group (schizophrenia \< control; p \< 0.05)

Chi square (schizophrenia \> control; p \< 0.05)

Main effect of age group (older \< younger; p \< 0.05)
